512 related articles for article (PubMed ID: 28103901)
21. Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration.
Tsika E; Kannan M; Foo CS; Dikeman D; Glauser L; Gellhaar S; Galter D; Knott GW; Dawson TM; Dawson VL; Moore DJ
Neurobiol Dis; 2014 Nov; 71():345-58. PubMed ID: 25174890
[TBL] [Abstract][Full Text] [Related]
22. The G2019S variant of leucine-rich repeat kinase 2 (LRRK2) alters endolysosomal trafficking by impairing the function of the GTPase RAB8A.
Rivero-Ríos P; Romo-Lozano M; Madero-Pérez J; Thomas AP; Biosa A; Greggio E; Hilfiker S
J Biol Chem; 2019 Mar; 294(13):4738-4758. PubMed ID: 30709905
[TBL] [Abstract][Full Text] [Related]
23. The LRRK2 signalling system.
Price A; Manzoni C; Cookson MR; Lewis PA
Cell Tissue Res; 2018 Jul; 373(1):39-50. PubMed ID: 29308544
[TBL] [Abstract][Full Text] [Related]
24. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity.
West AB; Moore DJ; Choi C; Andrabi SA; Li X; Dikeman D; Biskup S; Zhang Z; Lim KL; Dawson VL; Dawson TM
Hum Mol Genet; 2007 Jan; 16(2):223-32. PubMed ID: 17200152
[TBL] [Abstract][Full Text] [Related]
25. Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers.
Zhao Y; Perera G; Takahashi-Fujigasaki J; Mash DC; Vonsattel JPG; Uchino A; Hasegawa K; Jeremy Nichols R; Holton JL; Murayama S; Dzamko N; Halliday GM
Brain; 2018 Feb; 141(2):486-495. PubMed ID: 29253086
[TBL] [Abstract][Full Text] [Related]
26. LRRK2 phosphorylation of auxilin mediates synaptic defects in dopaminergic neurons from patients with Parkinson's disease.
Nguyen M; Krainc D
Proc Natl Acad Sci U S A; 2018 May; 115(21):5576-5581. PubMed ID: 29735704
[TBL] [Abstract][Full Text] [Related]
27. Protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants.
Heckman MG; Elbaz A; Soto-Ortolaza AI; Serie DJ; Aasly JO; Annesi G; Auburger G; Bacon JA; Boczarska-Jedynak M; Bozi M; Brighina L; Chartier-Harlin MC; Dardiotis E; Destée A; Ferrarese C; Ferraris A; Fiske B; Gispert S; Hadjigeorgiou GM; Hattori N; Ioannidis JP; Jasinska-Myga B; Jeon BS; Kim YJ; Klein C; Kruger R; Kyratzi E; Lin CH; Lohmann K; Loriot MA; Lynch T; Mellick GD; Mutez E; Opala G; Park SS; Petrucci S; Quattrone A; Sharma M; Silburn PA; Sohn YH; Stefanis L; Tadic V; Tomiyama H; Uitti RJ; Valente EM; Vassilatis DK; Vilariño-Güell C; White LR; Wirdefeldt K; Wszolek ZK; Wu RM; Xiromerisiou G; Maraganore DM; Farrer MJ; Ross OA;
Neurobiol Aging; 2014 Jan; 35(1):266.e5-14. PubMed ID: 23962496
[TBL] [Abstract][Full Text] [Related]
28. Overview of the Impact of Pathogenic LRRK2 Mutations in Parkinson's Disease.
Ito G; Utsunomiya-Tate N
Biomolecules; 2023 May; 13(5):. PubMed ID: 37238714
[TBL] [Abstract][Full Text] [Related]
29. Functional Analyses of Two Novel LRRK2 Pathogenic Variants in Familial Parkinson's Disease.
Coku I; Mutez E; Eddarkaoui S; Carrier S; Marchand A; Deldycke C; Goveas L; Baille G; Tir M; Magnez R; Thuru X; Vermeersch G; Vandenberghe W; Buée L; Defebvre L; Sablonnière B; Chartier-Harlin MC; Taymans JM; Huin V
Mov Disord; 2022 Aug; 37(8):1761-1767. PubMed ID: 35708213
[TBL] [Abstract][Full Text] [Related]
30. LRRK2 links genetic and sporadic Parkinson's disease.
Kluss JH; Mamais A; Cookson MR
Biochem Soc Trans; 2019 Apr; 47(2):651-661. PubMed ID: 30837320
[TBL] [Abstract][Full Text] [Related]
31. LRRK2 Phosphorylation: Behind the Scenes.
De Wit T; Baekelandt V; Lobbestael E
Neuroscientist; 2018 Oct; 24(5):486-500. PubMed ID: 29385885
[TBL] [Abstract][Full Text] [Related]
32. The Parkinson's-disease-associated mutation LRRK2-G2019S alters dopaminergic differentiation dynamics via NR2F1.
Walter J; Bolognin S; Poovathingal SK; Magni S; Gérard D; Antony PMA; Nickels SL; Salamanca L; Berger E; Smits LM; Grzyb K; Perfeito R; Hoel F; Qing X; Ohnmacht J; Bertacchi M; Jarazo J; Ignac T; Monzel AS; Gonzalez-Cano L; Krüger R; Sauter T; Studer M; de Almeida LP; Tronstad KJ; Sinkkonen L; Skupin A; Schwamborn JC
Cell Rep; 2021 Oct; 37(3):109864. PubMed ID: 34686322
[TBL] [Abstract][Full Text] [Related]
33. LRRK2 and mitochondria: Recent advances and current views.
Singh A; Zhi L; Zhang H
Brain Res; 2019 Jan; 1702():96-104. PubMed ID: 29894679
[TBL] [Abstract][Full Text] [Related]
34. LRRK2 Expression Is Deregulated in Fibroblasts and Neurons from Parkinson Patients with Mutations in PINK1.
Azkona G; López de Maturana R; Del Rio P; Sousa A; Vazquez N; Zubiarrain A; Jimenez-Blasco D; Bolaños JP; Morales B; Auburger G; Arbelo JM; Sánchez-Pernaute R
Mol Neurobiol; 2018 Jan; 55(1):506-516. PubMed ID: 27975167
[TBL] [Abstract][Full Text] [Related]
35. LRRK2 and idiopathic Parkinson's disease.
Rocha EM; Keeney MT; Di Maio R; De Miranda BR; Greenamyre JT
Trends Neurosci; 2022 Mar; 45(3):224-236. PubMed ID: 34991886
[TBL] [Abstract][Full Text] [Related]
36. Dysregulated phosphorylation of Rab GTPases by LRRK2 induces neurodegeneration.
Jeong GR; Jang EH; Bae JR; Jun S; Kang HC; Park CH; Shin JH; Yamamoto Y; Tanaka-Yamamoto K; Dawson VL; Dawson TM; Hur EM; Lee BD
Mol Neurodegener; 2018 Feb; 13(1):8. PubMed ID: 29439717
[TBL] [Abstract][Full Text] [Related]
37. The APP intracellular domain promotes
Zhang ZW; Tu H; Jiang M; Vanan S; Chia SY; Jang SE; Saw WT; Ong ZW; Ma DR; Zhou ZD; Xu J; Guo KH; Yu WP; Ling SC; Margolin RA; Chain DG; Zeng L; Tan EK
Sci Signal; 2022 Aug; 15(748):eabk3411. PubMed ID: 35998231
[TBL] [Abstract][Full Text] [Related]
38. Upregulation of the p53-p21 pathway by G2019S LRRK2 contributes to the cellular senescence and accumulation of α-synuclein.
Ho DH; Seol W; Son I
Cell Cycle; 2019 Feb; 18(4):467-475. PubMed ID: 30712480
[TBL] [Abstract][Full Text] [Related]
39. LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson's disease patients.
Ysselstein D; Nguyen M; Young TJ; Severino A; Schwake M; Merchant K; Krainc D
Nat Commun; 2019 Dec; 10(1):5570. PubMed ID: 31804465
[TBL] [Abstract][Full Text] [Related]
40. LRRK2 and Parkinson's Disease: From Lack of Structure to Gain of Function.
Blanca Ramírez M; Madero-Perez J; Rivero-Rios P; Martinez-Salvador M; Lara Ordonez AJ; Fernandez B; Fdez E; Hilfiker S
Curr Protein Pept Sci; 2017; 18(7):677-686. PubMed ID: 26965688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
